A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) Using an Administrative Healthcare Database in France

09/08/2024
04/06/2025
EU PAS number:
EUPAS1000000247
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

A3921403_PROTOCOL- FRANCE DUS_V4.0_26FEB2024.pdf

English (1.85 MB - PDF) View document
Study results
Study report
Other information